CytomX Therapeutics (CTMX)
Develops tumor-localized, conditionally activated oncology biologics through its PROBODY platform.
$2.78
vs last close−0.17 (−5.61%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 26 | 27 | 41 | 25 | 33 | 38 | 51 | 19 | 6 | 1 | 10 | 1 |
| Cost of revenue | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross profit | 25 | 27 | 41 | 25 | 33 | 38 | 51 | 19 | 6 | 1 | 10 | 1 |
| 14 | 27 | 30 | 34 | 29 | 20 | 28 | 20 | 22 | 29 | 30 | 25 | |
| Research & development | 10 | 19 | 22 | 25 | 21 | 15 | 19 | 13 | 15 | 21 | 19 | 18 |
| 3 | 8 | 8 | 8 | 8 | 6 | 9 | 7 | 6 | 7 | 11 | 8 | |
| General & administrative | 0 | 8 | 8 | 8 | 8 | 6 | 9 | 7 | 6 | 7 | 11 | 8 |
| Other expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income | 11 | −1 | 12 | −8 | 4 | 18 | 23 | −1 | −16 | −28 | −20 | −24 |
| −5 | 3 | 2 | 2 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 3 | |
| Interest income | 3 | 3 | 2 | 2 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 3 |
| Other non-operating income | 5 | −3 | −2 | −2 | −2 | −1 | −1 | −1 | −2 | −1 | −1 | −3 |
| Income before tax | 6 | 2 | 14 | −6 | 6 | 19 | 24 | 0 | −14 | −26 | −18 | −21 |
| Income tax expense | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | 3 | 1 | 14 | −7 | 6 | 19 | 24 | 0 | −14 | −27 | −18 | −21 |
| Net income | 3 | 1 | 14 | −7 | 6 | 19 | 24 | 0 | −14 | −27 | −18 | −21 |
| EPS, basic | $0.04 | $0.01 | $0.17 | −$0.08 | $0.07 | $0.24 | $0.27 | −$0.00 | −$0.09 | −$0.17 | −$0.10 | −$0.09 |
| EPS, diluted | $0.04 | $0.01 | $0.17 | −$0.08 | $0.07 | $0.24 | $0.27 | −$0.00 | −$0.09 | −$0.17 | −$0.10 | −$0.09 |
| Weighted average shares, basic | 81 | 67 | 82 | 85 | 85 | 80 | 87 | 129 | 165 | 170 | 177 | 219 |
| Weighted average shares, diluted | 81 | 67 | 83 | 85 | 85 | 80 | 87 | 129 | 165 | 170 | 177 | 219 |
| EBITDA | 7 | 2 | 14 | −6 | 6 | 19 | 24 | 0 | −14 | −26 | −18 | −20 |
| Depreciation & amortization | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| EBIT | 6 | 2 | 14 | −6 | 6 | 19 | 24 | 0 | −14 | −26 | −18 | −21 |